Rocket Lab Corporation (RKLB)

Rocket Lab Corporation (RKLB) rallied 26.31% over the past week and closed up 5.49% on the last session, but the stock remains well below its 200-day average. The move comes after a quarterly report on November 9, 2026 in which adjusted EPS of -$0.12 missed the analysts' estimate of -$0.07, yet the shares rose 6.54% in the first session afterward. The stock sits at 25% of its 52-week range, above its 50-day and 20-day averages but 15.76% below the 200-day average, which is the level that matters most for the trend.

The stock rose 6.54% in the first session after the November 9, 2026 report, even though adjusted EPS of -$0.12 missed the analysts' estimate of -$0.07 by 71.43%. Revenue grew 61.99% year on year in the latest quarter, far faster than the sector median of 11.7%, and the market appears to be weighing that growth more heavily than the loss. No cause for the move has been reported, so the reaction is best read as the market's response rather than a confirmed explanation.

Earnings per share over the last 12 months were -$0.37 on a reported basis, so the price-to-earnings ratio is not meaningful. Net profit margin is -25.7% and operating margin is -27.64%, and return on equity of -6.41% trails the sector median of 17.8%. The balance sheet is lightly indebted, with a debt-to-equity ratio of 0.02, which limits financial risk even as operations remain unprofitable.

Of 22 analysts, 18 rate the stock buy or strong buy, 4 hold it and none sell it, up from 14 buy ratings out of 18 three months earlier. Insiders, by contrast, sold $980.1M of stock over the last 18 months in 62 sales and made no open-market purchases. Insider sales are often planned in advance or made to cover tax on vesting shares, so they are a weaker signal than open-market buying.

The base case is that RKLB trades in a wide range while it works back toward its 200-day average of $78.52. Revenue growth of 61.99% in the latest quarter and analysts' expectation of 59.4% growth this fiscal year are the main support. Analysts' 12-month targets run from $64.00 to $150.00, with a median of $102.50, and 18 of 22 rate the stock buy or strong buy. Progress depends on narrowing losses: analysts expect a per-share loss of -$0.27 this fiscal year and -$0.09 next year, and the stock remains unprofitable. A sustained move above $78.52 would signal a shift in the trend; a break below $57.75 would open the path toward the 52-week low of $37.57. With a beta of 3.18 and a typical daily move of 6.13%, the stock can swing sharply in either direction on news.